MEDIROM Healthcare Technologies

MEDIROM Healthcare Technologies, Inc. owns, develops, operates, manages, and supports relaxation salons through the franchising and direct ownership of such salons. It provides relaxation and bodywork services. The firm operates two synergistic lines of businesses: Relaxation Salon Segment (retail) and Digital Preventative Healthcare Segment (healthtech). The company was founded by Kouji Eguchi in July 2000 and is headquartered in Tokyo, Japan.

MEDIROM Healthcare Technologies, Inc. owns, develops, operates, manages, and supports relaxation salons through the franchising and direct ownership of such salons. It provides relaxation and bodywork services. The firm operates two synergistic lines of businesses: Relaxation Salon Segment (retail) and Digital Preventative Healthcare Segment (healthtech). The company was founded by Kouji Eguchi on July 13, 2000 and is headquartered in Tokyo, Japan.

Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5% Total Customers Served: 75,760 – Sales Per Customer: JPY 7,055 – Customer Repeat Ratio: 77.5%

MEDIROM Healthcare Technologies Inc. Announces November 2024 Key Performance Indicators (KPIs)

TOKYO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) announces that its subsidiary MEDIROM MOTHER Labs Inc. raised to date an aggregate total of 260.3 million yen (approximtaely USD $ [1.7] million calculated at an exchange rate of JPY[153.64] to US$1) at a pre-money equity valuation of JPY9 billion (approximately USD $ [58.6] million calculated at an exchange rate of JPY[153.64] to US$1) in its Series A equity financing. NFES Technologies Inc. is the lead investor in the financing round, and several public companies in Japan, including M3, Inc. (TOKYO PRIME: 2413) and Elematec Corporation (TOKYO PRIME: 2715), as well as certain individual investors are also participating. The Series A equity financing round is still ongoing. MEDIROM MOTHER Labs has closed financings with six investors to date and intends to conclude the financing round by December 31, 2024. “We are very excited that our MEDIROM MOTHER Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc. as well as M3,Inc and Elematec Corporation. The pre money valuation of 9 billion yen is approximately multiples of MEDIROM's current NASDAQ listing market capitalization which I believe further validates our technology, business model and growth potential.” said Kouji.

MEDIROM Healthcare Technology‘s Subsidiary, MEDIROM MOTHER Labs, Raises an Aggregate Total of JPY260.3 Million in its Series A Financing Round

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the closing of its public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000 before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount.

MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering

TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”) announces that two senior executives, Issei Homan, Chief Technology Officer of MEDIROM MOTHER Labs Inc. (“Mother Labs”), a subsidiary of MEDIROM, and Yasuhiro Hayami, Chief Business Officer of Mother Labs, invested in Mother Labs' Series A financing at a pre-money valuation of of JPY9 billion (as of December 1, 2024, approximately USD $59,000,000). Messrs. Homan and Hayami are committed senior executives of Mother Labs and share MEDIROM's corporate philosophy and vision as well as commitment to future growth potential.

Two Senior MEDIROM Mother Labs Executives Invest in Mother Labs' Series A Financing at a Pre-Money Valuation of JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000)

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the pricing of a public offering of 2,860,000 American Depositary Shares at a public offering price of $1.75 per share, for gross proceeds of approximately $5,000,000, before deducting underwriting discounts and offering expenses. In addition, MEDIROM has granted the underwriters a 45-day option to purchase up to an additional 429,000 American Depositary Shares to cover over-allotments at the public offering price, less the underwriting discount. The Offering is expected to close on December 11, 2024, subject to the satisfaction of customary closing conditions.

MEDIROM Healthcare Technologies Inc. Announces Pricing of Public Offering

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. has received orders for over 25,000 MOTHER Bracelet units, including orders from Japanese companies such as NFES Technologies Inc.

UPDATE: MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units

MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units

TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09

M3 Group Joins MEDIROM Mother Labs' Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation

TOKYO--(BUSINESS WIRE)-- #InvestorRelations--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) , announced a business alliance with MEDIROM Healthcare Technologies Inc.(Nasdaq: MRM) .

SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance

TOKYO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”) is pleased to announce that it is capitalizing on its extensive experience operating wellness clinics and healthcare technology to expand into the rehabilitation industry. In doing so, MEDIROM established a wholly-owned subsidiary, MEDIROM Rehab Solutions Inc., which acquired all of the rehabilitation centers of Y's, Inc. Prior to the acquisition by MEDIROM Rehab Solutions Inc., Y's, Inc. owned and operated ten cerebral infarction rehabilitation centers in Tokyo and other major cities across Japan.

MEDIROM Rehab Solutions Inc. Acquires Rehabilitation Centers from Y's, Inc.

NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen

Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies

TOKYO, July 22, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that its subsidiary MEDIROM Rehab Solutions Inc. entered into an agreement to purchase a rehabilitation business from Y's, Inc., a Japanese corporation, as of July 10, 2024.

MEDIROM Healthcare Technologies Announces Business Transfer from Y's, Inc.

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (“we”, “our”, “us” or “the Company”) hereby announces that the Company plans to acquire a majority of Japan Gene Medicine Corporation (the “Target Company”). On June 30, 2024, the Company entered into a share transfer agreement (the "Share Transfer Agreement") to acquire 70.0% of the shares of the Target Company from an individual shareholder. The Company has also entered into a legally binding memorandum of understanding (the "Additional Transfer Memorandum of Understanding"), effective as of June 30, 2024, to obtain an option to acquire the remaining 30.0% of the Target Company's shares from the seller. The closings of the transactions under the Share Transfer Agreement and Additional Transfer Memorandum of Understanding are each subject to certain conditions. Certain of these closing conditions under the Share Transfer Agreement are summarized below.

MEDIROM Healthcare Technologies Announces Acquisition of Japan Gene Medicine Corporation

Four Nasdaq-listed Japanese Companies Gather to Showcase the Appeal of Japanese Companies to the World Four Nasdaq-listed Japanese Companies Gather to Showcase the Appeal of Japanese Companies to the World

The first JAPAN IR Event 2024 was held at Nasdaq's U.S. headquarters

TOKYO, June 25, 2024 (GLOBE NEWSWIRE) --  MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”), a holistic healthcare company based in Japan, announced it filed its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC"), including consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), on June 18, 2024.

MEDIROM Healthcare Technologies Inc. Announces Financial Results for Fiscal Year 2023

NEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM”, the “Company”), today announced it will participate in a “NASDAQ JAPAN IR EVENT” to be held at Nasdaq MarketSite in Times Square on June 20, 2024. Five companies are currently expected to join this event (including one private company), and we will share information about the attractive nature of the Japanese market with a global audience.

“NASDAQ JAPAN IR EVENT” to Be Held at Nasdaq MarketSite on June 20, 2024

TOKYO, April 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its major Key Performance Indicators, or KPIs, updated for the month of March 2024. Data is provided for all salons for which comparative financial and customer data is available and excludes certain salons where such information is not available.

MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) --  MEDIROM Healthcare Technologies Inc. (“we”, “our” or “us”) hereby announces that we resolved, at a meeting of our Board of Directors held on March 29, 2024, to enter into a Memorandum of Understanding (the “MOU”) for the purpose of acquiring all of the shares of stock of Japan Gene Medicine Corporation (the “Target Company”) and making it our subsidiary, and commencing the processes and negotiations necessary to enter into the definitive agreement for the transaction. The MOU was executed on April 2, 2024.

Announcement Execution of Memorandum of Understanding for Share Acquisition (Subsidiarization)

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission (the "SEC") on May 30, 2023. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at http://www.sec.gov as well as through the Company's investor relations website at https://medirom.co.jp/en/ir/.

MEDIROM Healthcare Technologies Inc. Files Its Annual Report on Form 20-F

National HealthCare

PORTLAND, Maine--( BUSINESS WIRE )--North Haven Capital (NHC), a private investment group based in Portland, Maine announced today that it has made an investment into Morgan Records Management LLC (MRM). NHC teamed up with Eastern Bank, A full service, local commercial bank with a growing $5 billion commercial lending portfolio. Eastern prides itself as local with high touch service.

North Haven Capital Announces Investment into Morgan Records Management

NEW YORK--( BUSINESS WIRE )--MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that COZY LLC (“COZY”), a company owned and controlled by Mr. Kouji Eguchi, the CEO and controlling shareholder of the Company, has entered into a stock repurchase plan (the “Plan”) with a U.S. investment bank, under which COZY may purchase up to JPY50 million of the Company's American Depositary Shares (“ADSs”), each representing one common share of the Company. On January 18, 2023, the Board of Directors of the Company approved the Plan.

MEDIROM Healthcare Technologies Inc. Announces Up to JPY 50 Million Stock Repurchase Plan by its Controlling Shareholder and CEO

NEW YORK--( BUSINESS WIRE )--MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company”), today announced its preliminary, unaudited financial results for the year ended December 31, 2022, prepared under Japanese GAAP (“JGAAP”). These preliminary financial results and management's estimates included in this press release are unreviewed, unaudited, and preliminary, are prepared solely in accordance with JGAAP, have not been reviewed or audited under U.S. GAAP, and are based solely on information available to the management of the Company and management's assumptions and expectations as of the date of this press release, which remain subject to change. Actual results for the year ended December 31, 2022 remain subject to the completion of management's reviews and reconciliations and/or adjustments under U.S. GAAP, the Company's other financial closing procedures, and the audit by the independent auditor in accordance with U.S. GAAP, and may differ from these estimated preliminary results due to the completion of the Company's financial closing procedures, the audit under U.S. GAAP, and other developments that may arise during the audit process. Accordingly, you should not place undue reliance on this preliminary information. See “Important Notice Regarding these Preliminary Financial Results and Management's Estimates” below.

MEDIROM Healthcare Technologies Inc. Announces Preliminary, Unaudited Financial Results for Full Year 2022 under Japanese GAAP

Total Customers Served: 71,770 – Sales Per Customer: JPY 6,505 – Customer Repeat Ratio: 80.8% Total Customers Served: 71,770 – Sales Per Customer: JPY 6,505 – Customer Repeat Ratio: 80.8%

MEDIROM Healthcare Technologies Inc. Announces September 2022 Key Performance Indicators (KPIs)

Total Customers Served: 72,250 – Sales Per Customer: JPY 6,705 – Customer Repeat Ratio: 80.1% Total Customers Served: 72,250 – Sales Per Customer: JPY 6,705 – Customer Repeat Ratio: 80.1%

MEDIROM Healthcare Technologies Inc. Announces August 2022 Key Performance Indicators (KPIs)

Total Customers Served: 76,521 – Sales Per Customer: JPY 6,511 – Customer Repeat Ratio: 80.6% Total Customers Served: 76,521 – Sales Per Customer: JPY 6,511 – Customer Repeat Ratio: 80.6%

News for MEDIROM Healthcare Technologies Stock (MRM)